These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34289425)

  • 21. The Swedish version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Construct validity and interrater reliability.
    von Knorring L; Lindström E
    Acta Psychiatr Scand; 1992 Dec; 86(6):463-8. PubMed ID: 1281960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PANSS-6: a brief rating scale for the measurement of severity in schizophrenia.
    Østergaard SD; Lemming OM; Mors O; Correll CU; Bech P
    Acta Psychiatr Scand; 2016 Jun; 133(6):436-44. PubMed ID: 26558537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can the Positive and Negative Syndrome scale (PANSS) differentiate treatment-resistant from non-treatment-resistant schizophrenia? A factor analytic investigation based on data from the Pattern cohort study.
    Freitas R; Dos Santos B; Altamura C; Bernasconi C; Corral R; Evans J; Malla A; Krebs MO; Nordstroem AL; Zink M; Haro JM; Elkis H
    Psychiatry Res; 2019 Jun; 276():210-217. PubMed ID: 31108345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early perception of medication benefit predicts subsequent antipsychotic response in schizophrenia: "the consumer has a point" revisited.
    Ascher-Svanum H; Weiden P; Nyhuis AW; Faries DE; Stauffer V; Kollack-Walker S; Kinon BJ
    Clin Schizophr Relat Psychoses; 2014 Jul; 8(2):84-90, 90A. PubMed ID: 23446198
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics.
    Chen YL; Chen KP; Chiu CC; Tai MH; Lung FW
    BMC Psychiatry; 2018 Dec; 18(1):376. PubMed ID: 30509308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia.
    Harvey RC; James AC; Shields GE
    CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and tolerability of ziprasidone versus risperidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder: an 8-week, double-blind, multicenter trial.
    Addington DE; Pantelis C; Dineen M; Benattia I; Romano SJ
    J Clin Psychiatry; 2004 Dec; 65(12):1624-33. PubMed ID: 15641867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antipsychotic treatment response in schizophrenia.
    Gardner KN; Bostwick JR
    Am J Health Syst Pharm; 2012 Nov; 69(21):1872-9. PubMed ID: 23111671
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
    Tollefson GD; Andersen SW
    J Clin Psychiatry; 1999; 60 Suppl 5():23-9; discussion 30. PubMed ID: 10192404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
    Robb AS; Carson WH; Nyilas M; Ali M; Forbes RA; Iwamoto T; Assunção-Talbott S; Whitehead R; Pikalov A
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):33-8. PubMed ID: 20166794
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Equipercentile linking of the BPRS and the PANSS.
    Leucht S; Rothe P; Davis JM; Engel RR
    Eur Neuropsychopharmacol; 2013 Aug; 23(8):956-9. PubMed ID: 23433639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A four-dimensional model of chronic schizophrenia based on the factorial structure of the Positive and Negative Syndrome Scale (PANSS). A study of a group of 153 chronic schizophrenic patients and comparison with the factorial structure of the BPRS].
    Loas G; Noisette C; Legrand A; Delahousse J
    Encephale; 1997; 23(1):10-8. PubMed ID: 9172962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: an analysis of the CATIE Schizophrenia Trial.
    Glick HA; Li P; Harvey PD
    Schizophr Res; 2015 Aug; 166(1-3):110-4. PubMed ID: 26044113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insight and medication adherence in schizophrenia: An analysis of the CATIE trial.
    Kim J; Ozzoude M; Nakajima S; Shah P; Caravaggio F; Iwata Y; De Luca V; Graff-Guerrero A; Gerretsen P
    Neuropharmacology; 2020 May; 168():107634. PubMed ID: 31077729
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A study of the interrelationship between and comparative interrater reliability of the SAPS, SANS and PANSS.
    Norman RM; Malla AK; Cortese L; Diaz F
    Schizophr Res; 1996 Mar; 19(1):73-85. PubMed ID: 9147498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Validity and Sensitivity of PANSS-6 in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Study.
    Østergaard SD; Foldager L; Mors O; Bech P; Correll CU
    Schizophr Bull; 2018 Feb; 44(2):453-462. PubMed ID: 28575321
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M
    J Clin Psychiatry; 2004 Apr; 65(4):551-6. PubMed ID: 15119920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale.
    Pilla Reddy V; Kozielska M; Johnson M; Mafirakureva N; Vermeulen A; Liu J; de Greef R; Rujescu D; Groothuis GM; Danhof M; Proost JH
    J Clin Psychopharmacol; 2013 Dec; 33(6):731-9. PubMed ID: 24113674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Large-scale evaluation of the Positive and Negative Syndrome Scale (PANSS) symptom architecture in schizophrenia.
    Lim K; Peh OH; Yang Z; Rekhi G; Rapisarda A; See YM; Rashid NAA; Ang MS; Lee SA; Sim K; Huang H; Lencz T; Lee J; Lam M
    Asian J Psychiatr; 2021 Aug; 62():102732. PubMed ID: 34118560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.